Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 17 · below the Ichimoku cloud · RSI 24 (oversold) · MACD below its signal
| 7.19 | 52-week high | +100.84% |
| 6.20 | Previous month high | +73.18% |
| 5.86 | Previous week high | +63.69% |
| 4.67 | Previous month low | +30.45% |
| 4.26 | Previous week low | +18.99% |
| 4.14 | R3 (classic) | +15.55% |
| 3.93 | R2 (classic) | +9.87% |
| 3.74 | R1 (classic) | +4.38% |
| 3.73 | Previous day high | +4.19% |
| 3.58 | Price now | |
| 3.53 | Pivot | −1.30% |
| 3.34 | S1 (classic) | −6.80% |
| 3.33 | Previous day low | −6.98% |
| 3.13 | S2 (classic) | −12.48% |
| 2.94 | S3 (classic) | −17.97% |
| 1.00 | 52-week low | −72.07% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $627.7K | 0.00% | 129.70K | −35% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ANTX trade in the reports read so far (1,240 of 1,244; the rest are being read now).
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.9 | -2.7 | 210.9 | 33.0 | -4.8 | 11.8 | 10.5 | 3.7 | -4.1 | -32.7 | +214.0% | ||
| 2025 | -17.4 | 0.0 | 19.3 | -8.8 | -14.5 | 0.0 | 0.0 | 3.8 | 15.5 | -3.1 | -11.4 | 4.6 | −17.4% |
| 2024 | -5.8 | -84.6 | 9.1 | -26.2 | -17.1 | 8.0 | 18.6 | -55.7 | -5.3 | 0.9 | 54.6 | -17.4 | −93.3% |
| 2023 | 27.6 | -7.2 | -12.5 | -20.5 | -28.5 | 51.5 | -4.5 | 85.2 | 6.9 | -10.3 | 21.8 | 16.6 | +115.0% |
| 2022 | 3.7 | -4.0 | -48.3 | 10.5 | 100.2 | 1.4 | -17.0 | -30.9 | -4.4 | −36.8% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 11, 2026 | Marks Gilbert LynnDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Oct 11, 2026 | Martin Patricia ADirector | Stock Award(Grant) at price 0.00 per share. | 389 | — |
| Oct 11, 2026 | Aziz KabeerDirector | Stock Award(Grant) at price 0.00 per share. | 2.5K | — |
| Sep 8, 2026 | Readnour Robin ShaneDirector | Sale at price 6.02 per share. | 1.1K | $6.67K |
| Sep 7, 2026 | Readnour Robin ShaneDirector | Sale at price 6.02 - 6.07 per share. | 16.1K | $97.32K |
| Aug 31, 2026 | Fitzpatrick Margaret MDirector | Purchase at price 5.53 per share. | 2.1K | $11.60K |
| Aug 31, 2026 | Williams Sarah JoanneOfficer | Sale at price 5.53 per share. | 272 | $1.50K |
| Aug 16, 2026 | Readnour Robin ShaneDirector | Sale at price 6.01 per share. | 35.4K | $212.70K |
| Aug 13, 2026 | Zakrzewski Joseph SDirector | Stock Gift at price 0.00 per share. | 405.9K | — |
| Jul 9, 2026 | Marks Gilbert LynnDirector | Stock Award(Grant) at price 0.00 per share. | 2.8K | — |
| Jul 9, 2026 | Martin Patricia ADirector | Stock Award(Grant) at price 0.00 per share. | 766 | — |
| Jul 9, 2026 | Aziz KabeerDirector | Stock Award(Grant) at price 0.00 per share. | 2.9K | — |
| Jul 7, 2026 | Eizen Joshua MChief Operating Officer | Sale at price 4.17 per share. | 5.9K | $24.80K |
| May 28, 2026 | Williams Sarah JoanneOfficer | Sale at price 4.43 per share. | 265 | $1.17K |
| Apr 9, 2026 | Marks Gilbert LynnDirector | Stock Award(Grant) at price 0.00 per share. | 3.8K | — |
| Apr 9, 2026 | Martin Patricia ADirector | Stock Award(Grant) at price 0.00 per share. | 1.2K | — |
| Apr 9, 2026 | Aziz KabeerDirector | Stock Award(Grant) at price 0.00 per share. | 3.8K | — |
| Mar 2, 2026 | Williams Sarah JoanneOfficer | Sale at price 1.06 per share. | 327 | $347 |
| Feb 19, 2026 | Chanda SanjayOfficer | Stock Award(Grant) at price 0.00 per share. | 38K | — |
| Feb 19, 2026 | Day Lucy O.Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 38K | — |
Buy / hold / sell counts
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.